PRLD vs REGN · rev $6.5M vs P/E 14, rev $14.34B
Prelude Therapeutics Inc (PRLD) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported PRLD revenue for 2025-09-30 was $6.5M. Net income was -$83.0M. Revenue was up 116.7% from 2024-09-30 to 2025-09-30. PRLD currently screens at market cap $346.5M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
PRLD currently screens at market cap $346.5M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the PRLD and REGN stock pages for the full models.
Not investment advice.